Literature DB >> 9093429

Regular production of infective sporozoites of Plasmodium falciparum and P. vivax in laboratory-bred Anopheles albimanus.

S Hurtado1, M L Salas, J F Romero, J C Zapata, H Ortiz, M Arevalo-Herrera, S Herrera.   

Abstract

One of the major constraints for studies on the sporogonic cycle of the parasites causing human malaria, and on the protective efficacy of pre-erythrocytic vaccines, is the scarcity of laboratory-reared Anopheles mosquitoes as a source of infective sporozoites. The aim of the present study was to reproduce the life-cycles of Plasmodium falciparum and P. vivax in the laboratory and so develop the ability to produce infective sporozoites of these two species regularly under laboratory conditions. Colonized Anopheles albimanus, of Buenaventura and Tecojate strains, were infected by feeding either on Plasmodium-infected blood, from human patients or experimentally inoculated Aotus monkeys, or on gametocytes of the P. falciparum NF-54 isolate grown in vitro. The monkeys were infected with the blood stages of a Colombian P. vivax isolate and then, after recovery, with the Santa Lucia strain of P. falciparum from El Salvador. Although both of the mosquito strains used were successfully infected with both parasite species, the Buenaventura strain of mosquito was generally more susceptible to infection than the Tecojate strain, and particularly to infection with the parasites from the patients, who lived where this strain of mosquitoes was originally isolated. Monkeys injected intravenously with the P. vivax sporozoites produced in the mosquitoes developed patent sexual and asexual parasitaemias; the gametocytes that developed could then be used to infect mosquitoes, allowing the development of more sporozoites. However, experimental infections failed to establish after the P. falciparum sporozoites were used to inoculate monkeys. The ability to reproduce the complete life cycle of P. vivax in the laboratory, from human to mosquito and then to monkey, should greatly facilitate many studies on vivax malaria and on the efficacy of candidate malaria vaccines. The availability of the sporogonic cycles of P. falciparum from three different sources should also permit a variety of biological studies.

Entities:  

Mesh:

Year:  1997        PMID: 9093429     DOI: 10.1080/00034983.1997.11813111

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  15 in total

Review 1.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

2.  Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Authors:  Myriam Arévalo-Herrera; Liliana Soto; Blanca Liliana Perlaza; Nora Céspedes; Omaira Vera; Ana Milena Lenis; Anilza Bonelo; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

3.  Characterization of Plasmodium vivax transmission-blocking activity in low to moderate malaria transmission settings of the Colombian Pacific coast.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Leonardo Rocha; Diego Alvarez; John C Beier; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

4.  Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.

Authors:  Myriam Arévalo-Herrera; Omaira Vera; Angélica Castellanos; Nora Céspedes; Liliana Soto; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

5.  Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.

Authors:  Sócrates Herrera; Yezid Solarte; Alejandro Jordán-Villegas; Juan Fernando Echavarría; Leonardo Rocha; Ricardo Palacios; Oscar Ramírez; Juan D Vélez; Judith E Epstein; Thomas L Richie; Myriam Arévalo-Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

6.  Plasmodium vivax sporozoite production in Anopheles albimanus mosquitoes for vaccine clinical trials.

Authors:  Yezid Solarte; María R Manzano; Leonardo Rocha; Hugo Hurtado; Mark A James; Myriam Arévalo-Herrera; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

7.  Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites.

Authors:  Alejandro Jordán-Villegas; Anilza Bonelo Perdomo; Judith E Epstein; Jesús López; Alejandro Castellanos; María R Manzano; Miguel A Hernández; Liliana Soto; Fabián Méndez; Thomas L Richie; Stephen L Hoffman; Myriam Arévalo-Herrera; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

8.  Successful sporozoite challenge model in human volunteers with Plasmodium vivax strain derived from human donors.

Authors:  Sócrates Herrera; Olga Fernández; María R Manzano; Bermans Murrain; Juana Vergara; Pedro Blanco; Ricardo Palacios; Juan D Vélez; Judith E Epstein; Mario Chen-Mok; Zarifah H Reed; Myriam Arévalo-Herrera
Journal:  Am J Trop Med Hyg       Date:  2009-11       Impact factor: 2.345

Review 9.  Plasmodium vivax: who cares?

Authors:  Mary R Galinski; John W Barnwell
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

10.  Plasmodium vivax sporozoite challenge in malaria-naïve and semi-immune Colombian volunteers.

Authors:  Myriam Arévalo-Herrera; David A Forero-Peña; Kelly Rubiano; José Gómez-Hincapie; Nora L Martínez; Mary Lopez-Perez; Angélica Castellanos; Nora Céspedes; Ricardo Palacios; José Millán Oñate; Sócrates Herrera
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.